Arcturus Therapeutics Holdings Inc., of San Diego, said it priced an underwritten public offering of 4.11 million shares at $17 each for expected gross proceeds of approximately $70 million. The underwriters have been granted a 30-day option to purchase up to an additional 617,647 shares of common stock at the public offering price. The company said it intends to use the net proceeds for working capital and general corporate purposes.
Athersys Inc., of Cleveland, said it priced its underwritten public offering of 22.25 million shares at $2.25 per share, for gross proceeds of approximately $50.1 million. The underwriters have been granted a 30-day option to purchase up to an additional 3.33 million shares. The company intends to use the net proceeds for working capital and general corporate purposes, including funding toward its acute respiratory distress syndrome (ARDS) clinical program, which includes initiation of a phase II/III pivotal study for COVID-19-induced ARDS patients, and its process development and manufacturing projects. Shares of Athersys (NASDAQ:ATHX) closed April 16 at $2.28, down 26%.
Calithera Biosciences Inc., of South San Francisco, said it priced its underwritten public offering, selling 5 million shares at $6.25 each, with gross proceeds expected to be $31.25 million. The underwriter has been granted a 30-day option to purchase up to 750,000 of additional shares of common stock at the public offering price. Shares of Calithera (NASDAQ:CALA) closed April 16 at $6.26, down 20%.
Leon-nanodrugs GmbH, of Munich, Germany, said it completed a series B funding round. It has also established a partnership with Hamburg, Germany-based Evotec SE, which made a strategic investment in Leon, that will leverage their combined expertise in nanomedicine development services. Leon expedites active pharmaceutical ingredients to deliver improved stability, increased solubility and enhanced bioavailability.